3 completed, 1 terminated. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Gem Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma GPX-150 for Injection - Soft Tissue Sarcoma | Phase 2 | Completed | Gem Pharmaceuticals | 22 | 2015-01-07 | 2018-01-10 |
| Safety Study of GPX-150 in Patients With Solid Tumors GPX-150 for Injection - Advanced Solid Tumors - Phase 1 Population | Phase 1 | Completed | Gem Pharmaceuticals | 27 | 2008-01-01 | 2014-08-05 |
| Study of GPX-100 in the Treatment of Metastatic Breast Cancer GPX-100 (13-deoxydoxorubicin) - Breast Cancer, Metastasis | Phase 2 | Terminated | Gem Pharmaceuticals | 40 | 2005-03-01 | 2007-01-09 |
| GPX-100 in Treating Patients With Solid Tumors GPX-100 - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Gem Pharmaceuticals | 1999-08-01 | 2013-04-23 |
Breast Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Sarcoma (1)
5-imino-13-deoxydoxorubicin (2) · Injections (2)
United States (4) · Bulgaria (1)
Frederick J. Dechow, PhD (1) · John H. Ward, MD (1) · Mohammed Milhem, MD (1) · Raymond J Hohl, MD, PhD (1)